Orbach H, Ben-Yehuda A, Ben-Yehuda D, Manor D, Rubinow A, Naparstek Y
Department of Medicine, Hadassah University Hospital, Jerusalem, Israel.
J Rheumatol. 1995 Nov;22(11):2166-9.
We describe a 32-year-old woman who developed severe anemia due to pure red cell aplasia in the course of systemic lupus erythematosus (SLE). After failure of therapy with high doses of glucocorticoids and immunoglobulins, and despite high levels of endogenous erythropoietin, she was treated with human recombinant erythropoietin with dramatic and sustained improvement. Based on this case and on the literature review of erythropoietin therapy in pure red cell aplasia, we suggest that erythropoietin should be used in SLE associated pure red cell aplasia before cytotoxic therapy.
我们描述了一名32岁女性,她在系统性红斑狼疮(SLE)病程中因纯红细胞再生障碍性贫血而出现严重贫血。在大剂量糖皮质激素和免疫球蛋白治疗失败后,尽管内源性促红细胞生成素水平很高,但她接受了重组人促红细胞生成素治疗,病情得到显著且持续改善。基于该病例以及对纯红细胞再生障碍性贫血促红细胞生成素治疗的文献回顾,我们建议在细胞毒性治疗前,应将促红细胞生成素用于SLE相关的纯红细胞再生障碍性贫血。